Drug search by name

Eliglustat and Hepatic dysfunction

Result of checking the interaction of drug Eliglustat and disease Hepatic dysfunction for safety when used together.

Check result:

Eliglustat <> Hepatic dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of drugs eliglustat is contraindicated in patients with moderate or severe hepatic impairment and in those patients, who are CYP450 2D6 extensive metabolizers with mild hepatic impairment and taking a strong or moderate CYP450 2D6 inhibitor due to the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac intervals. This agent is contraindicated in patients who are CYP450 2D6 extensive metabolizers, intermediate metabolizers and taking a strong or moderate CYP450 2D6 inhibitor concomitantly with a strong or moderate CYP450 3A inhibitor. In the case of CYP450 2D6 intermediate metabolizers, or poor metabolizers, eliglustat is contraindicated in those patients with any degree of hepatic impairment or those taking a strong CYP450 3A inhibitor.

Eliglustat

Generic Name: eliglustat

Brand Name: Cerdelga

Synonyms: n.a.

What is Eliglustat?